AbCellera Biologics Inc. (ABCL) Stock Price & Analysis

AbCellera Biologics Inc. (ABCL) closed at USD 13.64 on Wednesday, October 28, 2026, up 6.31% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 12.83; the Oct 28, 2026 session ranged USD 12.65–13.65 on volume of 3,043,223 shares. Market capitalization is $4.42B, with a 52-week range of USD 2.75–15.02 (NMS). Source: Nexqual, retrieved October 28, 2026 at 23:05 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ABCL.md

Key facts (ABCL)

• Last four reported quarters (through Jun 30, 2026): revenue $66.2M, net income -$165M (-248.8% margin), free cash flow -$120M (SEC filings).
• Insider open-market purchases, last ~7 months: 5 Form 4 filings, $1.6M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 16.82 (range 9–30).
• Total return with dividends: 1Y +142.7% vs S&P 500 +13.6%; 5Y -13.2% vs S&P 500 +79.8%.
• Next earnings: 2026-11-09, EPS estimate USD -0.18, revenue estimate $6.2M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ABCL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ABCL)

P/S 66.8x · P/B 4.9x · FCF yield -2.71% · Earnings yield -3.73%

Insider purchases (SEC Form 4, open-market, last ~7 months) (ABCL)

5 purchases, $1.6M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ABCL)

Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 16.82 (low 9, high 30).

Rating changes, last 120 days:

Total return (dividends reinvested) (ABCL)

ABCL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ABCL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ABCL revenue by product line (quarter ended Jun 30, 2026)

ABCL revenue by region (fiscal year ended Dec 31, 2025)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ABCL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

Companies that name ABCL in their SEC reports

ABCL company outlook (results filed Aug 5, 2026)

• “AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments along with tiered royalties on net sales ranging from mid-single digits to low double digits. ● Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026. ● Announced the appointments of Dr.”

Quoted word-for-word from the SEC 8-K results press release.

ABCL analyst estimates and revisions

ABCL options: expected move

Options price a move of about ±18.7% (±$2.50) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±6.3% on average.

30-day implied volatility 91.8% vs 69.5% realized over the last 30 trading days. Put/call ratio (volume) 0.05. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 23:05 UTC)

Technical Analysis (ABCL)

Nexqual's technical model rates ABCL "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 28, 2026 at 23:05 UTC.

Analyst Ratings (ABCL)

Wall Street analysts rate ABCL "Buy" based on 12 analysts, with a mean price target of USD 16.82 (range USD 9–30), per Nexqual as of October 28, 2026 at 23:05 UTC.

Earnings (ABCL)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 23:05 UTC.

Financials & Fundamentals (ABCL)

Source: Nexqual, October 28, 2026 at 23:05 UTC.

Financial Health Score (ABCL)

Nexqual rates AbCellera Biologics Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 23:05 UTC.

Ownership (ABCL)

Source: Nexqual, October 28, 2026 at 23:05 UTC.

Leadership (ABCL)

AbCellera Biologics Inc. is led by Carl L.G. Hansen, CEO, President & Chairperson, per Nexqual as of October 28, 2026 at 23:05 UTC.

Major Backers & Investors (ABCL)

Notable institutional backers of AbCellera Biologics Inc. include Baker Bros. Advisors, LP, Capital Group, SmallCap World Fund Inc, according to Nexqual as of October 28, 2026 at 23:05 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 23:05 UTC.

From AbCellera Biologics Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• We anticipate initiating Phase 1/2 clinical trials for ABCL688 and ABCL386 in 2027. •Opened our clinical manufacturing facility, which completes a multi-year investment to build our integrated platform for creating antibody medicines.
• Our competitive advantage consists not of a single proprietary technology, but of the integration of proprietary know-how, specialized multidisciplinary teams, and the physical infrastructure necessary to advance programs from target to the clinic.
• We believe we have a competitive advantage in pursuing challenging, high-value targets, including: •GPCRs and Ion Channels: We have developed specialized capabilities to target complex transmembrane proteins.
• Since 2012, we have invested approximately $1 billion to build our platform.

Partnerships

• We discovered ABCL575 during our collaboration with EQRx Inc. ("EQRx") as part of a co-development program that began in 2021.
• In late 2023, with our platform near complete, we committed to transitioning from a partnership model to a clinical-stage biotechnology company developing our own pipeline of drug candidates.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not be able to file applications or amendments to commence additional clinical trials on the timelines we expect, and even if we are able to file as expected, the regulatory body may not permit us to proceed.
• Any regulatory approvals that we receive for our drug candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or subject to certain conditions of approval, and may contain requirements for potentially costly post-approval trials, and surveillance to monitor the safety and efficacy of the marketed drug.
• We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations that can harm our business.
• Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, more convenient or less expensive than any drugs we develop. Our competitors also may obtain regulatory approval for their drugs more rapidly, which could result in our competitors establishing a strong market position before we are able to enter the market.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 23:05 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt